Chitosan

Going Beyond Plastic: Chung-Ang University Team Explores Tara Gum as a Green Polymer

Retrieved on: 
Tuesday, January 16, 2024

SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Synthetic, non-biodegradable plastics are major sources of environmental pollution and have prompted a rising interest in sustainable, biodegradable alternatives derived from natural polymers. "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution. This natural, water-soluble substance contains polysaccharides (complex carbohydrates), including the widely used "galactomannan," which is employed in coatings, edible films, and as a stabilizer and thickener. The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery. Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.

Key Points: 
  • "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution.
  • The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery.
  • Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.
  • "The physicochemical property of tara gum and its products can be enhanced using various kinds of monomers, crosslinkers, or other polysaccharides.

BD Supports Hangzhou Singclean Medical's Global Strategic Expansion with a 300 Million RMB Medical Cosmetology Cooperation Announcement at CIIE

Retrieved on: 
Friday, November 10, 2023

Their shared goal is to introduce a wider range of Chinese-made medical cosmetology products to the global market.

Key Points: 
  • Their shared goal is to introduce a wider range of Chinese-made medical cosmetology products to the global market.
  • The signing ceremony was attended by Sun Weiqing, General Manager of Hangzhou Singclean Medical, and Jiang Wei, Vice President of Strategic Innovation and Business Excellence for BD Greater China.
  • At the CIIE, during the strategic cooperation agreement between Hangzhou Singclean Medical and BD, an intention to purchase BD Hylok™-based prefilled syringe products for 300 million RMB was reached.
  • Hangzhou Singclean Medical and BD Pharmaceutical Systems have been collaborating in the area of injectable medical products for a long period of time.

EQS-News: Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER

Retrieved on: 
Thursday, October 26, 2023

Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.

Key Points: 
  • Vancouver, BC, Canada, October 17th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM against cancer continues to develop and expand its applications.
  • The AccuTOXTM molecule can eradicate cancer cells via different mechanisms including the initiation of immunogenic cells death, endoplasmic reticulum stress and by causing direct damages to DNA.
  • AccuTOXTM triggers cancer tumor regression, Defence also recently demonstrated that encapsulated AccuTOXTM with chitosan nanoparticles triggers complete tumor regression in animals with pre-established solid lymphoma.
  • Further development and expanding applications on Defence’s leading AccuTOXTM therapeutic is ongoing and further news to be released upon results.

EQS-News: Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA

Retrieved on: 
Tuesday, October 17, 2023

The formulation was delivered twice with a 2 weeks interval and treated animals were followed for up to 40 days.

Key Points: 
  • The formulation was delivered twice with a 2 weeks interval and treated animals were followed for up to 40 days.
  • The tumors in animals treated with AccuTOXTM-Chitosan injections along with anti-PD-1 co-administration regressed and exhibited a prolonged survival rate.
  • The Defence team was able to bypass this limitation by encapsulating it into chitosan-based nanoparticles.
  • In addition to its agricultur al and industrial applications, chitosan is often useful in bandages to reduce bleeding and as an antibacterial agent.

Global Sustained Release Excipients Research Report 2023: Embracing the Future of Drug Delivery - The Growing Demand for Sustained-Release Excipients to 2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023

The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sustained Release Excipients Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In a rapidly evolving pharmaceutical landscape, the quest for more advanced drug delivery mechanisms is paramount.
  • Their role becomes increasingly essential as the global population grapples with both acute and chronic diseases.
  • The countries covered in the sustained-release excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

Retrieved on: 
Monday, September 18, 2023

“The formation of Novvae allows Virpax to focus exclusively on the development of its Rx product pipeline as we advance our lead product candidate, Probudur™ and prepare to enter Phase 2 human clinical trials in 2024.

Key Points: 
  • “The formation of Novvae allows Virpax to focus exclusively on the development of its Rx product pipeline as we advance our lead product candidate, Probudur™ and prepare to enter Phase 2 human clinical trials in 2024.
  • We are also looking to advance Envelta™ and expect to enter Phase 1 human clinical trials next year,” commented Anthony P. Mack , Chairman and CEO of Virpax Pharmaceuticals.
  • Additionally, Virpax is in advanced discussions for global rights of first refusal on two differentiated non-prescription assets.
  • Should the Company acquire these product candidates, they would be added to the Novvae pipeline.

THE TRŪ® SHRIMP COMPANIES, INC. APPOINTS BRIAN KNOCHENMUS AS PRESIDENT & CHIEF EXECUTIVE OFFICER

Retrieved on: 
Thursday, September 21, 2023

Knochenmus will be tasked with achieving trū Shrimp's next milestone of launching a commercial-scale production facility in Madison, SD.

Key Points: 
  • Knochenmus will be tasked with achieving trū Shrimp's next milestone of launching a commercial-scale production facility in Madison, SD.
  • Having spent the previous 25 years of his career with Ralco Nutrition, Inc., in roles ranging from production, marketing, Vice President, and most recently, President & CEO, Knochenmus brings his experience, vision and understanding of technology, food, and manufacturing.
  • trū Shrimp was born as a division of Ralco, out of a vision that Knochenmus had for revolutionizing the way shrimp are grown.
  • "I am thrilled to step into this role and bring to completion our dream of building a fully-integrated chitosan and shrimp business," said Knochenmus.

Chitosan biochemistry leader Tidal Vision® acquires strategic customer Clear Water Services™

Retrieved on: 
Tuesday, August 8, 2023

By leveraging Clear Water Services' mobile and modular water treatment systems, Tidal Vision® will be able to deploy their Tidal Clear® chitosan-based technologies in a wider range of applications to help solve some of humanity's greatest water pollution challenges.

Key Points: 
  • By leveraging Clear Water Services' mobile and modular water treatment systems, Tidal Vision® will be able to deploy their Tidal Clear® chitosan-based technologies in a wider range of applications to help solve some of humanity's greatest water pollution challenges.
  • In this alliance, Tidal Vision is allocating resources for Clear Water Services to build additional advanced water treatment systems, bolstering their already robust business model and fostering further expansion.
  • "I'm thrilled about our partnership with Tidal Vision," says Nate Holloway, President of Clear Water Services.
  • Clear Water Services captures real-time performance data within their water treatment systems, currently used to solve diverse pollution challenges at over 200 sites.

Live Cell Encapsulation - The Bioengineering Breakthrough Revolutionizing Therapeutics with Controlled Drug Delivery - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023

Live cell encapsulation, a cutting-edge bioengineering technology, entails encasing living cells with specialized materials or coatings.

Key Points: 
  • Live cell encapsulation, a cutting-edge bioengineering technology, entails encasing living cells with specialized materials or coatings.
  • Live cell encapsulation holds immense promise in the treatment of chronic diseases, including type 1 diabetes, cancer, and autoimmune disorders.
  • Notable partnerships and collaborations, like BIO INX and Nanoscribe's HYDROBIO INX N400, offering 3D printing-enabled cell encapsulation, underscore the potential of live cell encapsulation.
  • Detailed analysis of the major companies present in the Global Live Cell Encapsulation Market include:

Tidal Vision rebrands Tidal-Tex® division as Tidal-Tec™ Biomaterial Science, expands capabilities

Retrieved on: 
Wednesday, August 2, 2023

BELLINGHAM, Wash., Aug. 2, 2023 /PRNewswire/ -- As Madonna aptly expressed, "We are living in a material world." In response to the growing global appetite for safer materials that benefit both humanity and the planet, Tidal Vision announced today the re-envisioning of their Tidal-Tec™ Biomaterial Science division, formerly known as Tidal-Tex®. The company's cutting edge biomolecular technologies deliver consistent and scalable performance solutions for pressing challenges throughout material science.

Key Points: 
  • In response to the growing global appetite for safer materials that benefit both humanity and the planet, Tidal Vision announced today the re-envisioning of their Tidal-Tec™ Biomaterial Science division, formerly known as Tidal-Tex®.
  • The company's cutting edge biomolecular technologies deliver consistent and scalable performance solutions for pressing challenges throughout material science.
  • Tidal Vision's characterisation lab, led by Dr. Yonggang Liu, provides quality data by batch with new levels of precision.
  • This integrated partnership model offers materials companies a vertically integrated, stable, and cost-effective supply chain while providing the right solution for their current infrastructure.